BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Aug. 24, 2006
View Archived Issues
Ablynx €40M Round Notable Among European Financings
In one of the largest European private placements conducted this year, Ablynx NV raised €40 million (US$51.2 million) in a Series C round to drive more of its programs into preclinical and clinical development. (BioWorld Today)
Read More
Theravance's Phase III Data: Non-Inferior To Vancomycin
Read More
Debate Over Whether New Stem Cell Science Will Change Policy
Read More
Kemia Adds $31M In Series C, Reports Positive Phase I Data
Read More
Theratechnologies SPA Aligns Second TH9507 Pivotal Study
Read More
Other News To Note
Read More
Clinic Roundup
Read More
U.S. Patent Disclosures
Read More